With its new COVID-19 vaccine, Pfizer and BioNTech are hoping to get forward of worsening results of omicron in addition to any new variants.
Jonas Roosens/Belga Magazine/AFP by way of Getty Photographs
disguise caption
toggle caption
Jonas Roosens/Belga Magazine/AFP by way of Getty Photographs
With its new COVID-19 vaccine, Pfizer and BioNTech are hoping to get forward of worsening results of omicron in addition to any new variants.
Jonas Roosens/Belga Magazine/AFP by way of Getty Photographs
Pfizer and BioNTech have begun a scientific trial to judge a brand new, omicron-specific vaccine for COVID-19, the pharmaceutical firms introduced Tuesday.
Although people who find themselves vaccinated and boosted seem like higher protected in opposition to extreme illness and hospitalization from omicron, the extremely contagious variant has nonetheless led to breakthrough instances and a surge in general infections internationally.
“Whereas present analysis and real-world information present that boosters proceed to supply a excessive stage of safety in opposition to extreme illness and hospitalization with Omicron, we acknowledge the must be ready within the occasion this safety wanes over time and to probably assist tackle Omicron and new variants sooner or later,” Kathrin U. Jansen, Pfizer’s senior vp and head of vaccine analysis and growth, stated in an announcement.
The research will embody as many as 1,420 contributors divided into three teams.
One group contains individuals who have already acquired two doses of the present Pfizer-BioNTech vaccine and also will obtain the omicron vaccine. One other contains these with three doses of the present Pfizer vaccine who may also get the omicron vaccine. The third group contains unvaccinated individuals who will obtain three pictures of the omicron vaccine.
The Meals and Drug Administration has licensed the present Pfizer-BioNTech COVID-19 vaccine for emergency use in folks ages 5 and older. The Moderna and Johnson & Johnson vaccines are licensed for adults.
A model of this story initially appeared within the Morning Version stay weblog.
